KieuhoaTranVoMD

Pediatric Hematology & Oncology • San Francisco, CA

Associate Professor, Pediatrics, UCSF School of Medicine

Request Appointment

Overview of Dr. Vo

Dr. Kieuhoa Vo is a pediatric hematologist/oncologist in San Francisco, CA and is affiliated with multiple hospitals in the area, including UCSF Benioff Children's Hospital Oakland and UCSF Benioff Childrens Hospital. She received her medical degree from Indiana University School of Medicine and has been in practice 9 years. She is one of 55 doctors at UCSF Benioff Children's Hospital Oakland and one of 19 doctors at UCSF Benioff Childrens Hospital who specialize in Pediatric Hematology & Oncology. She has more than 20 publications and over 300 citings.

Office
1825 4th Sreet
6TH floor
San Francisco, CA 94143
Book by Phone+1(844) 771-3081

Fax+1 415-353-2657

Education & Training

University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 2012 - 2015
Nationwide Children's Hospital/Ohio State UniversityResidency, Pediatrics, 2008 - 2011
Indiana University School of MedicineClass of 2008

Certifications & Licensure

CA State Medical License 2012 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE Start of enrollment: 2021 Aug 28
Active, not recruiting
Roles: Contact
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial Start of enrollment: 2024 Jul 01
Not yet recruiting
Phase 2
Roles: Contact
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Nov 14
Active, not recruiting
Phase 2
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane Start of enrollment: 2023 Oct 10
Recruiting
Phase 1
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Available
Olaparib With Ceralasertib in Recurrent Osteosarcoma Start of enrollment: 2020 Nov 24
Recruiting
Phase 2
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Start of enrollment: 2022 Jan 28
Recruiting
Phase 1, Phase 2
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Start of enrollment: 2022 Nov 17
Recruiting
Phase 1, Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Start of enrollment: 2021 Nov 08
Recruiting
Phase 1, Phase 2
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects Start of enrollment: 2019 Oct 21
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

36 citations
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi
Nature Medicine. 2023-05-01
14 citations
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine
Kelly E. Huibregtse, Kieuhoa T. Vo, Steven G. DuBois, Stephanie Fetzko, John Neuhaus
European Journal of Cancer. 2016-10-01
1 citations
Pediatric neuroblastoma with intraspinal extension: the role of surgical management.
Diana Chang, Taemin Oh, Jarod L Roland, Katherine K Matthay, Kieuhoa T Vo
Journal of Neurosurgery. Pediatrics. 2024-03-01

Grant Support

Circulating biomarkers of clinical response to combination targeted therapies in neuroblastomaNIH/NCI2024–2029

Professional Memberships

American Society of Clinical Oncology - ASCO
Member